EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Predischarge Betamethasone in Infants Diagnosed With Bronchopulmonary Dysplasia

Tal-El Ernest, Doreen Ozalvo, Orna Staretz-Chacham, Kyla A Marks, Eilon Shany iD, Daniela Landau, Justin Richardson

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71201 ↗

At a glance

Journal article in Pediatric Pulmonology, 2025. Written by Tal-El Ernest and 6 co-authors. Institution: Neonatal Department and Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University of the Negev, Beersheba, Israel. Major MEDLINE topics: Betamethasone, Bronchopulmonary Dysplasia, Oxygen Inhalation Therapy, Glucocorticoids. 16 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: The authors received no specific funding for this work..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The aim of this study was to assess the influence of a short betamethasone therapy course for infants diagnosed with BPD on the need of oxygen therapy after discharge home, on post‐menstrual age (PMA) discharge, and on hospital readmission rates.

Methods

This was a retrospective cohort study that included infants born and diagnosed with BPD in the Soroka University Medical Center neonatal department between 2012 and 2020. Demographic and clinical parameters were extracted from computerized medical files.

Results

Overall, 187 infants were included in the study; 151 (81%) were treated with betamethasone, of them 110 (73%) were discharged home without supplemental oxygen. Nonsignificant differences were found between infants treated with or without betamethasone regarding home oxygen supplementation at discharge (27% treated vs. 17% without, p = 0.192) and PMA at discharge (40.2 weeks treated vs. 41.2 weeks not treated, p = 0.114). Of the infants receiving betamethasone, those weaned from oxygen were discharged home at an earlier PMA (39.6 ± 5.0 vs. 42.0 ± 3.7 week, p < 0.001) and there was no difference between readmission rates due to respiratory problems of infants discharged home without oxygen supplementation to those discharged with oxygen (37/108 [34%] vs. 14/36 [39%], p = 0.615). In multivariable analysis, respiratory support at 36 weeks PMA (odds ratio: 4.4 [CI: 1.5–13.2], p < 0.009) and receiving two or more courses of betamethasone (odds ratio: 3.6 [CI: 1.2–10.5], p = 0.009) were significant predictors for need of oxygen supplementation at discharge.

Conclusions

Use of corticosteroids for infants diagnosed with BPD may shorten hospital stay by promoting weaning from oxygen therapy.

Subjects

MeSH terms (MEDLINE)

BetamethasoneBronchopulmonary DysplasiaOxygen Inhalation TherapyGlucocorticoidsHumansRetrospective StudiesMaleFemaleInfant, NewbornPatient ReadmissionPatient DischargeInfant

Substances

BetamethasoneGlucocorticoids

Authors and institutions

  • Neonatal Department and Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University of the Negev, Beersheba, Israel.

ORCID profiles: Eilon Shany

Funding

  • The authors received no specific funding for this work.

Cite

APA

Ernest, T. E., Ozalvo, D., Staretz-Chacham, O., Marks, K. A., Shany, E., Landau, D., & Richardson, J. (2025). Predischarge Betamethasone in Infants Diagnosed With Bronchopulmonary Dysplasia. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71201

Vancouver

Ernest TE, Ozalvo D, Staretz-Chacham O, Marks KA, Shany E, Landau D, et al. Predischarge Betamethasone in Infants Diagnosed With Bronchopulmonary Dysplasia. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71201

BibTeX
@article{Ernest2025,
  author = {Ernest, Tal-El and Ozalvo, Doreen and Staretz-Chacham, Orna and Marks, Kyla A and Shany, Eilon and Landau, Daniela and Richardson, Justin},
  title = {Predischarge Betamethasone in Infants Diagnosed With Bronchopulmonary Dysplasia},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71201}
}
Start for free →